Pasireotide and mifepristone: New options in the medical management of cushing's disease

Endocrine Practice

Volumn 20, Issue 1, 2014, Pages 84-93

  Cohan, Pejman ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INCRETIN; MIFEPRISTONE; PASIREOTIDE; HYDROCORTISONE RECEPTOR; SOMATOSTATIN;

CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; CUSHING SYNDROME; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; GLUCAGON RELEASE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LONG TERM CARE; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; ORAL GLUCOSE TOLERANCE TEST; PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; STEROIDOGENESIS; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; PITUITARY ACTH HYPERSECRETION; SECRETION (PROCESS);

ADRENOCORTICOTROPIC HORMONE; HUMANS; MIFEPRISTONE; PITUITARY ACTH HYPERSECRETION; RECEPTORS, GLUCOCORTICOID; SOMATOSTATIN;

EID: 84892725887     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13127.RA     Document Type: Review

References (41)

1. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484.
2. Biller BMK, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
3. Liubinas SV, Porto LD, Kaye AH. Management of recurrent Cushing's disease. J Clin Neurosci. 2011;18:7-12.
4. Rizk A, Honegger J, Milian M, Psaras T. Treatment options in Cushing's disease. Clin Med Insights Oncol. 2012;6:75-84.
5. Nagesser SK, van Seters AP, Kievit J, et al. Treatment of pituitary-dependent Cushing's syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol (Oxf). 2000;52:427-435.
6. Kelly DF. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus. 2007;23:E5.
7. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549-559.
8. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
9. Fleseriu M, Petersenn S. Medical management of Cushing's disease: what is the future? Pituitary. 2012;15:330-341.
10. Korlym™ (mifepristone) full prescribing information. Corcept Therapeutics Inc 2012.Novartis Pharmaceuticals. Signifor Prescribing Information. 2012. Available at: http://www.pharma.us.novartis.com/cs/www. pharma.us.novartis.com/product/pi/pdf/signifor.pdf. Accessed September 5, 2013.
11. Sartor O, Cutler GB Jr. Mifepristone: treatment of Cushing's syndrome. Clin Obstet Gynecol. 1996;39: 506-510.
12. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007;157:561-569.
13. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med.1997;48:129-156.
14. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017.
15. Strowski MZ, Dashkevicz MP, Parmar RM, et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology. 2002;75:339-346.
16. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56:579-584.
17. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94: 1118-1124.
18. Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol. 2008;286:199-205.
19. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-716.
20. Schmid HA, Silva AP. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35.
21. Hofland LJ, Van Der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152: 645-654.
22. Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049.
23. ClinicalTrials.gov. NCT00936741. 2013. Available at: http:// clinicaltrials.gov/show/NCT00936741. Accessed September 5, 2013.
24. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.
25. Zambre Y, Ling Z, Chen MC, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57:1159-1164.
26. Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007; 92:673-680.
27. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol.1999;20:157-198.
28. Henry RR, Mudaliar S, Wetli-Hermosillo K, Ligueros-Saylan M, Chenji S, Golor G. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Abstracts. 2011;26:P260.
29. Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Diabetes Metab. 2013;39:34-41.
30. Pivonello R, van Gaal L, Salgado LR, et al. Long-term use of pasireotide results in sustained reductions in UFC and continued improvements in signs and symptoms in patients with Cushing's disease. In: Program of the 15th Congress of the European Neuroendocrine Association, September 12-15, 2012; Vienna, Austria. Abstract OC05.
31. ClinicalTrials.gov. NCT01582061. 2013. Available at: http:// clinicaltrials.gov/show/NCT01582061. Accessed September 5, 2013.
32. European Medicines Authority. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/07/ WC500146613.pdf. Accessed September 5, 2013.
33. FDA Drug Safety Communications. FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362444.pdf. Accessed September 5, 2013.
34. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848.
35. Valassi E, Crespo I, Gich I, Rodríguez J, Webb SM. A reappraisal of the medical therapy with steroidgenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf). 2012;77:735-742.
36. Castinetti F, Morange I, Jaquet P, Conte-Devoix B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008;158:91-99.
37. Winquist EL, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol 1995;13:157-164.
38. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716.
39. Lila AR, Gopal RA, Acharya SV, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010;16:968-976.
40. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13:123-129.
41. Pivonello R, De Martino MC, Cappabiana P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.